Alafi Christopher D, Director, added 100,000 shares of Intra-Cellular Therapies, Inc. (ITCI) to its portfolio at the rate of $12.56 per share valuing $1,256,350 on May 14. The insider has now 4,053,270 shares of the company to its portfolio. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of Intra-Cellular Therapies, Inc. (ITCI) was $12.84. Currently, the 1st Resistance Point for this stock is $13.20, with a 2nd Resistance Point sitting at $13.56. Meanwhile, this company’s stock has a 1st Support Level at $12.16 and a 2nd Support Level at $11.48. Intra-Cellular Therapies, Inc. (ITCI) stock has gained $1.56, or 13.83%, in the past five days. In the last full month, these shares have gained $1.12, or 9.56%. In the past three months, this stock’s price has fallen by -$0.43, or -3.24%. This year-to-date, Intra-Cellular Therapies, Inc. (ITCI) shares have gained $1.45, or 12.73%.
Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For Intra-Cellular Therapies, Inc. (ITCI) stock, 40% of short-term indicators suggest that these shares are a “ Sell .” Meanwhile, 25% of medium-term indicators point to this stock being a “ Buy .” Looking further ahead, 0% of long-term indicators suggest that this stock is a “ Hold .”
With 55,117 K shares outstanding, this company currently has a market capitalization of $651,483K. Intra-Cellular Therapies, Inc. (ITCI) generates annual net income of -$155,130 K. This stock has generated a 1-Year Total Return of -39.41%, a 3-Year Total Return of -65.70%, and a 5-year Total Return of -33.33%. This stock’s 5-Year Dividend Growth is 0.00%. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.
In the most recently-reported fiscal quarter, which ended in Mar-19, Intra-Cellular Therapies, Inc. (ITCI) reported earnings of -$0.63 per share. Wall Street analysts, on average, were expecting the company to report earnings of -$0.88 per share, representing a 0.25 difference and -28.00% surprise. In the previous quarter ending in Dec-18, the reported earnings of -$0.75 represented a 0.16 difference from the consensus estimate calling for -$0.91 per share, which was a -17.18% surprise.
For the current fiscal quarter, which is set to end in 06/2019, the average earnings estimate is -$0.86 per share. This estimate came from a total of 3 Wall Street Analysts. Of those market experts, the high estimate was -$0.77 and the low estimate was -$1.01. In the year-ago quarter, Intra-Cellular Therapies, Inc. (ITCI) generated per-share earnings of -$0.68. If the analysts are correct about the current quarter’s earnings, the growth will be -26.47% .
Turning our focus now to insider trading activity, there have been 6 purchases (43,986 shares in total) and 1 sale (20,000 shares in total) in the last 3 months. In the last 6 months, there have been 31 insider buys amounting to 250,893 shares and 22 insider sales amounting to 186,014 shares. In the past full year, 42 insider purchases were made (involving 320,088 shares) and 25 insider sell-offs equivalent to 218,913 shares.
Moving onto liquidity, Intra-Cellular Therapies, Inc. (ITCI) has a Current Ratio of 9.79, a Quick Ratio of 9.79 and a Cash Ratio of 9.57.